PT Kalbe Farma Tbk (PTKFF)
0.0926
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
PT Kalbe Farma Enterprise Value: 4.167B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 4.167B |
| May 30, 2024 | 4.167B |
| May 29, 2024 | 4.167B |
| May 28, 2024 | 4.167B |
| May 24, 2024 | 4.167B |
| May 23, 2024 | 4.167B |
| May 22, 2024 | 4.167B |
| May 21, 2024 | 4.167B |
| May 20, 2024 | 4.167B |
| May 17, 2024 | 4.167B |
| May 16, 2024 | 4.167B |
| May 15, 2024 | 4.167B |
| May 14, 2024 | 4.167B |
| May 13, 2024 | 4.167B |
| May 10, 2024 | 4.167B |
| May 09, 2024 | 4.167B |
| May 08, 2024 | 4.167B |
| May 07, 2024 | 4.167B |
| May 06, 2024 | 4.167B |
| May 03, 2024 | 4.167B |
| May 02, 2024 | 4.047B |
| May 01, 2024 | 4.047B |
| April 30, 2024 | 4.047B |
| April 29, 2024 | 4.047B |
| April 26, 2024 | 4.047B |
| Date | Value |
|---|---|
| April 25, 2024 | 4.047B |
| April 24, 2024 | 4.047B |
| April 23, 2024 | 4.047B |
| April 22, 2024 | 4.047B |
| April 19, 2024 | 4.047B |
| April 18, 2024 | 4.047B |
| April 17, 2024 | 4.047B |
| April 16, 2024 | 4.047B |
| April 15, 2024 | 4.047B |
| April 12, 2024 | 4.047B |
| April 11, 2024 | 4.047B |
| April 10, 2024 | 4.047B |
| April 09, 2024 | 4.047B |
| April 08, 2024 | 4.047B |
| April 05, 2024 | 4.047B |
| April 04, 2024 | 4.047B |
| April 03, 2024 | 4.047B |
| April 02, 2024 | 4.047B |
| April 01, 2024 | 4.047B |
| March 31, 2024 | 4.047B |
| March 28, 2024 | 4.091B |
| March 27, 2024 | 4.091B |
| March 26, 2024 | 4.091B |
| March 25, 2024 | 4.091B |
| March 22, 2024 | 4.091B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
470.24M
Minimum
Mar 26 2020
7.782B
Maximum
Dec 31 2022
4.919B
Average
4.762B
Median
Oct 08 2020
Enterprise Value Benchmarks
| Taihe Group Inc | -- |
| CEL-SCI Corp | 60.22M |
| AIM ImmunoTech Inc | 10.88M |
| IGC Pharma Inc | 29.80M |
| NovaBay Pharmaceuticals Inc | 4.387M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 61.09M |
| Revenue (Quarterly) | 533.54M |
| Total Expenses (Quarterly) | 455.56M |
| EPS Diluted (Quarterly) | 0.0013 |
| Gross Profit Margin (Quarterly) | 39.71% |
| Profit Margin (Quarterly) | 11.45% |
| Earnings Yield | 4.34% |
| Operating Earnings Yield | 5.64% |
| Normalized Earnings Yield | 4.341 |